Section Arrow
Quote
FTRE.NASDAQ
- Fortrea Holdings
Quotes are at least 15-min delayed:2026/10/18 21:42 EDT
Regular Hours
Last
 22.49
-0.255 (-1.12%)
Day High 
23.135 
Prev. Close
22.745 
1-M High
23.51 
Volume 
1.90M 
Bid
21.75
Ask
23.51
Day Low
21.86 
Open
23.04 
1-M Low
19.05 
Market Cap 
2.16B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 20.97 
20-SMA 20.43 
50-SMA 19.12 
52-W High 23.51 
52-W Low 8.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.83/1.96
Enterprise Value
3.27B
Balance Sheet
Book Value Per Share
5.51
Cash Flow
Cash Flow Yield
0.11
Income Statement
Total Revenue
2.70B
Operating Revenue Per Share
32.40
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.